HIV Drug Dolutegravir Linked to Cardiovascular Defects in Zebrafish Embryos

Dolutegravir has become one of the most widely prescribed drugs in the global fight against HIV. It belongs to a newer class of antiretrovirals called integrase strand-transfer inhibitors, and it has done what the earlier generation of HIV medications could not: it has dramatically reduced the death rate from infection, turning a diagnosis that once meant certain decline into a manageable chronic condition. But a new study in zebrafish embryos suggests the drug may carry a hidden cost for pregnant women and their developing children.

Researchers exposed zebrafish embryos to dolutegravir at concentrations comparable to therapeutic levels in humans. What they observed was striking: the embryos developed severe cardiovascular damage. Fluid accumulated in the pericardium—the sac surrounding the heart—and internal bleeding appeared. Blood flow through vessels slowed dramatically. The heartbeat itself became irregular and weak. These were not subtle changes detectable only through molecular analysis. They were visible, measurable, and profound.

The damage intensified at a dose of 1 micromolar, where the researchers documented a cascade of structural defects. The heart's chambers—the atria and ventricles—shrank noticeably. The normal looping pattern that the heart undergoes during development went awry. The network of blood vessels failed to form properly. Under the microscope, the embryos showed the signature of a drug interfering with the most basic processes of cardiac construction.

To understand how dolutegravir was causing this damage, the team analyzed gene expression in the exposed embryos. They found disruption in eight genes critical to heart and blood vessel development: myh6 and myl7, which organize the contractile machinery of heart muscle; vegfaa, kdrl, and flt1, which direct the formation of new blood vessels; hif1aa, which responds to oxygen availability; and runx1 and gata1a, which regulate blood cell formation. The drug was not simply poisoning the tissue. It was scrambling the genetic instructions that tell an embryo how to build a functioning cardiovascular system.

This finding arrives at a moment of particular urgency. Dolutegravir is the preferred first-line treatment for HIV in many parts of the world, including sub-Saharan Africa, where the burden of HIV in pregnancy is heaviest. Previous research had already raised concerns about the drug's link to neural tube defects—malformations of the brain and spinal cord—when used during early pregnancy. Those studies prompted some health authorities to recommend caution in women of childbearing age. Now the cardiovascular findings add another layer of concern.

It is crucial to note what this study does and does not show. The researchers worked with zebrafish embryos, not human pregnancies. The genetic pathways they identified are conserved across vertebrates, meaning they function similarly in fish and humans, but that similarity is not identity. No human cases of dolutegravir-related cardiovascular birth defects have been documented or reported in the scientific literature. The study is exploratory—it identifies a mechanism and a risk signal, not a proven harm in clinical practice.

Yet the findings are specific enough and the biological plausibility strong enough that they warrant serious attention from clinicians and public health officials. For pregnant women living with HIV, the calculus is already complex: the benefits of viral suppression for maternal health and the prevention of mother-to-child transmission must be weighed against any potential risks to fetal development. If dolutegravir does indeed carry cardiovascular embryotoxic potential at therapeutic doses, that balance shifts. The question now is whether human studies will confirm what the zebrafish model has suggested, and if so, whether alternative antiretrovirals might offer safer options for women in early pregnancy.